Privia Health Execs Flip Shares on 10b5‑1 Plan, Swapping Low‑Priced Buys for Mid‑$20s Gains Amid Massive Option Roll‑Offs

Insider Trading Pulse: Privia Health Group’s Latest Moves

Strategic Buying by Morris Matthew Shawn On May 1, 2026, owner Morris Matthew Shawn executed a Rule 10b5‑1 purchase of 17,096 shares of Privia Health Group at an average price of $2.00. This trade, part of a pre‑planned schedule, added 85,284 shares to his holdings, bringing his stake above 68,000 shares. The purchase came at a time when the stock was trading near its 52‑week low of $18.77, yet the company’s price momentum was still positive (12.51 % monthly). The buy was reported after a modest uptick in social media sentiment (+4) and a moderate buzz (58 %)—suggesting that the trade was largely procedural rather than reactionary.

Pattern of “Buy‑Sell” Cycles Shawn’s recent activity reveals a recurring pattern: he buys at the low end of the price spectrum ($2–$3) and sells shortly after when the share price rebounds to the mid‑$20s. For example, on May 4 he bought 1,017 shares for $2.00 and sold the same quantity at $24.96 the same day, capturing a 1,200 % return. Similar cycles occurred in late February and December 2025. These “buy‑sell” loops, executed under a Rule 10b5‑1 plan, indicate a disciplined, calendar‑based strategy that relies on volatility rather than insider information.

Implications for Investors Shawn’s trades suggest confidence in the company’s long‑term trajectory—he consistently holds a sizable block (≈68,000 shares) despite frequent short‑term flips. However, the sheer volume of options exercised (over 3.6 million shares) signals a substantial liquidity event that could impact the share price if exercised in bulk. For investors, the key takeaway is that Shawn’s activity is largely systematic, not opportunistic, but the large option roll‑offs could create short‑term volatility. Monitoring the timing of these option expiries will be crucial.

Profile of Morris Matthew Shawn Shawn is a long‑standing insider whose transactions date back to at least December 2025. His trading history shows:

He has never been flagged for insider trading violations and all trades are executed under a Rule 10b5‑1 plan, implying a pre‑determined schedule. His consistent holding of ~68,000 shares underscores a long‑term stake in the business, while the periodic flips reflect a strategy to lock in gains when the stock spikes.

Company‑Wide Insider Activity Beyond Shawn, EVP David Mountcastle has been the most active insider, buying and selling in the same price range as Shawn. The pattern across senior executives—buy low, sell high—suggests a shared belief that the stock’s current valuation underestimates its potential. Mountcastle’s recent 144‑rule filing, detailing a limited sale of shares, further confirms that management is comfortable liquidating positions when the market rewards the company’s growth prospects.

Bottom Line for Investors

• Long‑Term Confidence: Shawn and Mountcastle maintain sizeable holdings, implying confidence in Privia’s platform and growth trajectory.
• Short‑Term Volatility: Large option expiries and systematic trades can generate price swings, especially during earnings or regulatory announcements.
• Watch the Calendar: The 10b5‑1 plan’s schedule is the main driver; any deviation or unexpected sale could signal a shift in sentiment.

For those tracking Privia Health Group, the insider activity is a useful barometer of executive conviction, but investors should remain cautious of the potential for short‑term price volatility driven by planned option exercises and strategic trades.